pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,534 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1212Endpoints919BioPharma Dive354BioSpace335Fierce Biotech316onclive165raps111globenewswire health
therapy area
allOncology8159Rare Disease1937Cardiology1879Immunology1565Hematology1354Pulmonology1264Vaccines
  • Elevance Health’s chief digital officer discusses practical AI applications for insurers
    Elevance Health interviewed its chief digital information officer, Ratnakar Lavu, about how health insurers are adopting artificial intelligence. Lavu, who previously held digital roles at Kohl’s,…
    Endpoints · 3mo agoNeutral↗ source
  • Axsome secures settlement to keep Sunosi exclusive until 2040
    Axsome Therapeutics announced it has reached a settlement that pushes back the entry of generic versions of its narcolepsy medication Sunosi until 2040. The agreement was reached with the last rem…
    Endpoints · 3mo agoRegulatoryPositive↗ source
← prev
page 45 of 62
next →
73
fda recalls72
fda medwatch62
fda press38
1262
Psychiatry & CNS889
Ophthalmology521
Pain503
Endocrinology & Metabolism495
Infectious Disease457
  • Regeneron expands partnership with CytomX as other pharma partners exit
    Regeneron announced it will deepen its collaboration with CytomX Therapeutics, a Bay Area biotech. The decision follows CytomX losing several partnership agreements with other large pharmaceutical…
    Endpoints · 3mo agoDealPositive↗ source
  • Eli Lilly signs up to $1.9B deal with Ascidian Therapeutics for RNA editing in kidney disease
    Ascidian Therapeutics recently presented early data indicating that its novel RNA‑editing approach to repair faulty genes appears safe in humans, focusing on kidney disease applications. Eli Lilly…
    Endpoints · 3mo agoDealPositive↗ source
  • Alnylam commits $30 million upfront to AI startup Inceptive for RNA research collaboration
    Alnylam Pharmaceuticals announced a new collaboration with Inceptive, a Silicon Valley biotech startup that focuses on RNA. The agreement includes an upfront payment of $30 million and is intended…
    Endpoints · 3mo agoDealPositive↗ source
  • Eli Lilly says its GLP-1 weight loss shot and pill now covered for millions of Americans
    Eli Lilly announced that its GLP-1 based weight-loss injection and oral medication have been added to the formularies of the three largest pharmacy benefit managers. The company said this move make…
    Endpoints · 3mo agoPositive↗ source
  • Mineralys Therapeutics raises funds ahead of pending lorundrostat hypertension approval
    Mineralys Therapeutics first came to market attention in 2021 when it licensed a novel hypertension candidate, lorundrostat, from Japan’s Tanabe Pharma, agreeing to a modest $1 million upfront paym…
    Endpoints · 3mo agoDealNeutral↗ source
  • FDA issues new guidance for pharma on discussing unapproved drugs with payors
    The FDA has released guidance aimed at biopharma companies that are preparing to launch new therapies before they receive formal approval. The advice focuses on how companies can inform health-pla…
    Endpoints · 3mo agoRegulatoryNeutral↗ source
  • Bristol Myers Squibb assesses AI spending after deploying tools to thousands of staff
    Bristol Myers Squibb has recently provided artificial intelligence applications to a large portion of its workforce. The company is now turning its attention to measuring the cost of these tools a…
    Endpoints · 3mo agoNeutral↗ source
  • Roche reports narrow failure of breast cancer pill in Phase 3 trial at ASCO
    Roche updated investors and the oncology community that its experimental breast cancer oral therapy did not meet its primary endpoint in a pivotal Phase 3 study. The data, presented at the America…
    Endpoints · 3mo agoNegative readoutNegative↗ source
  • Allen Institute launches multi-hundred-million-dollar effort to turn brain atlas data into neurodegenerative drug candidates
    The Allen Institute, a Seattle nonprofit known for basic brain research, announced a major new effort to move its brain‑atlas knowledge toward drug development. The program will invest several hun…
    Endpoints · 3mo agoPositive↗ source
  • FDA issues draft guidance outlining data flexibilities for cell and gene therapy developers
    The FDA released a draft guidance from its Center for Biologics Evaluation and Research (CBER) that clarifies how developers of cell and gene therapies can use existing data and prior knowledge in…
    Endpoints · 3mo agoRegulatoryNeutral↗ source
  • NewLimit secures $435M funding, valuation tops $3B, aims for human trials in 2027
    NewLimit, a Bay Area anti-aging biotech, announced a financing round that raised $435 million, valuing the company at more than $3 billion. The round is among the largest private biotech financing…
    Endpoints · 3mo agoDealPositive↗ source
  • Contraline secures $92.5M Series B to fund Phase 3 trial of male contraceptive gel
    Contraline, a startup developing a male contraceptive, announced it has closed a Series B financing round worth $92.5 million. The capital will be used to advance its candidate, referred to as NES…
    Endpoints · 3mo agoDealPositive↗ source
  • Travere Therapeutics pays $112 million upfront to China’s Everest Medicines to expand rare kidney disease pipeline
    Travere Therapeutics, a San Diego‑based biotech, announced a partnership with China‑based Everest Medicines to strengthen its rare kidney disease portfolio beyond its approved drug Filspari. Under…
    Endpoints · 3mo agoDealPositive↗ source
  • Legend Biotech reports first in vivo CAR-T data from Chinese lymphoma trial
    Legend Biotech has released its first in vivo CAR-T cell therapy data, marking the next step after its CAR-T product Carvykti. The data come from an investigator-initiated trial in China that enro…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Celcuity reports combo regimen with gedatolisib doubles progression‑free survival odds in late‑stage breast cancer
    Celcuity announced at ASCO 2026 that its experimental drug gedatolisib, used in a combination regimen, showed a significant improvement in a late‑stage breast cancer trial. The data revealed that…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Michigan lawmakers introduce bipartisan bill to curb China-U.S. biotech partnerships
    A bipartisan group of Michigan legislators has unveiled a new bill aimed at limiting cross-border transactions between Chinese and American biotechnology firms. The proposal, introduced by Rep. Jo…
    Endpoints · 3mo agoRegulatoryNegative↗ source
  • Abivax’s ulcerative colitis Phase 3 trial shows promising efficacy but cancer cases raise safety concerns
    Abivax announced that its Phase 3 maintenance trial in ulcerative colitis produced results it called “landmark,” showing the drug’s ability to keep patients in remission. The company emphasized th…
    Endpoints · 3mo agoNegative readoutNegative↗ source
  • Praxis Precision Medicines reports late-stage failure of seizure drug and pauses second trial
    Praxis Precision Medicines had enjoyed a period of momentum, reporting two notable clinical successes in the past eight months. The company’s pipeline had been viewed positively by investors and an…
    Endpoints · 3mo agoNegative readoutNegative↗ source
  • Eli Lilly gives hospitals five days to meet new 340B claims data policy or lose discounts
    Eli Lilly has told a group of hospitals they must adhere to a new claims data policy within five days or their participation in the 340B drug discount program will be terminated. The policy requir…
    Endpoints · 3mo agoRegulatoryNegative↗ source
  • ASCO 2026 hints at future role for VEGF-targeted cancer drugs as complement to immunotherapy
    At the recent ASCO meeting, experts discussed the outlook for VEGF-targeted therapies in oncology. Earlier hopes that this new class could match the blockbuster success of pembrolizumab (Keytruda)…
    Endpoints · 3mo agoNeutral↗ source
  • Fulcrum Therapeutics abandons its only sickle cell drug after FDA cites concerns linked to withdrawn cancer therapy
    Fulcrum Therapeutics announced it is ending development of its sole clinical‑stage sickle cell medicine. The move follows feedback from the U.S. Food and Drug Administration that referenced a rece…
    Endpoints · 3mo agoRegulatoryNegative↗ source
  • Obesity care startup Ilant Health secures $15M Series A funding
    Ilant Health, a startup focused on obesity care, announced a $15 million Series A financing round. The capital will be used to broaden its personalized treatment platform, which leverages virtual…
    Endpoints · 3mo agoDealPositive↗ source
  • Eli Lilly's $7B acquisition of Kelonia highlighted by full-cohort response in in-vivo CAR-T trial for multiple myeloma
    At ASCO 2026, Kelonia Therapeutics presented data on its in-vivo CAR-T platform for multiple myeloma. The report covered 18 patients treated with the therapy, all of whom showed encouraging outcom…
    Endpoints · 3mo agoDealPositive↗ source